Drugs targeted against protein kinases

Bibliography

• PETO J: Cancer epidemiology in the last century and the next decade. Nature (2001) 411:390–395.
   PubMed Web of Science ®Google Scholar
• CHABNER BA, ALLEGRA CJ, CURT GA, CALABRESE P: In: Goodmann and Gilmann's the Pharmacological Basis of Therapeutics. Harden JG, Gilman AG, Lumbird LE (Eds.), McGraw Hill, New York, USA (1996):1233–1287.
   Google Scholar
• HORTOBAGYI GN: Developments in chemotherapy of breast cancer. Cancer (2000) 88:3073–3079.
   PubMedGoogle Scholar
• SPENCER A, O'BRIAN SG, GOLDMAN JM: Options for therapy in chronic myeloid leukemia. Br. J. Haematol. (1995) 91:2–6.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, WEINBERG RA: Hallmarks of cancer. Cell (2000) 100:57–70.
   PubMed Web of Science ®Google Scholar
• ••An excellent review that gives an overviewof cancer at the molecular, cellular and organ levels.
   Google Scholar
• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signaling. Nature (2001) 411:355–365.
   PubMed Web of Science ®Google Scholar
• ••Updated review on protein kinasescontaining a mine of information.
   Google Scholar
• HUNTER T: Signaling 2000 and beyond. Cell (2000) 100:113–127.
   Google Scholar
• EVAN GI, VOUSDEN K: Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 411:342–348.
   PubMed Web of Science ®Google Scholar
• ••Very good review.
   Google Scholar
• GIBBS J: Mechanism-based target identification and drug discovery in cancer research. Science (2000) 287:1969–1973.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on cancer drugdiscovery efforts.
   Google Scholar
• SRIDHAR R, HANSON-PAINTON O, COOPER DR et al.: Protein kinases as therapeutic targets. Pharm. Res. (2000) 17:1345–1353.
   PubMed Web of Science ®Google Scholar
• ••A recent review on kinases targeted fordrug development.
   Google Scholar
• HUBBARD SR: Structural analysis of receptor tyrosine kinases. Prog. Biophys. Md. Biol. (1999) 71:343–358.
   PubMed Web of Science ®Google Scholar
• •Reviews salient features from all known structures.
   Google Scholar
• BROWN NR, NOBLE ME, ENDICOTT JA, JOHNSON LN: The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. (1999) 1: 438–443.
   Google Scholar
• HUBBARD SR: Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. (1997) 16:5572–5581.
   PubMed Web of Science ®Google Scholar
• KNIGHTON DR, ZHENG J, TEN EYCK LF et al.: Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science (1991) 253:407–414.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, BORNMANN W, PELLICENA P, MILLER WT, CLARKSON B, KURIYAN J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science (2000) 289:1938–1942.
   PubMed Web of Science ®Google Scholar
• TOLEDO LM, LYDON NB ELBAUM D:The structure-based design of ATP-sitedirected protein kinase inhibitors. Curr.Med. Chem. (1999) 6:775-805. An excellent review.
   PubMedGoogle Scholar
• TRAXLER P, FURET P: Strategies towardthe design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. (1999) 82:195–206.
   PubMed Web of Science ®Google Scholar
• DEININGER MWN, GOLDMAN JM, MELO JV: The molecular biology of chronic myeloid leukemia. Blood (2000) 96:3343–3356.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nature Med. (1996) 5:561–566.
   Google Scholar
• •Important paper describing the activities of STI-571 on cell lines.
   Google Scholar
• DRUKER BJ, LYDON NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin. Invest. (2000) 105(1):3–7.
   PubMed Web of Science ®Google Scholar
• ••An excellent review from leaders involvedin the development of STI-571.
   Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl. J Med. (2001) 344:1031–1037.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038–1042.
   PubMed Web of Science ®Google Scholar
• ••First report describing the results ofclinical trials with STI-571.
   Google Scholar
• JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor 5TI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl. J. Med. (2001) 344:1052–1056.
   PubMed Web of Science ®Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science (2001) 293(5531):876–880.
   PubMed Web of Science ®Google Scholar
• HONG WK, ULLRICH AU: The role of EGFR in solid tumors and implications for therapy. Oncol. Therapeutics (2000) 1:1–30.
   Google Scholar
• HARARI D, YARDEN Y: Molecular mechanisms underlying ErbB2/Her-2 action in breast cancer. Oncogene (2000) 19:6102–6114.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science (1987) 235:177–182.
   PubMed Web of Science ®Google Scholar
• BASELGA J: Clinical trials of Herceptin (trastuzumab). Eur. j Cancer (2001) 37:S18–S24.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N EngL J Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• FAN Z, MENDELSOHN J: C225 mAb. Curr. Opin. Oncol. (1998) 10:67–75.
   PubMed Web of Science ®Google Scholar
• BOSCHELLI DH: Small molecule inhibitors of receptor tyrosine kinases. Drugs Future (1999) 24:515–537.
   Google Scholar
• FRY DW: Inhibition of epidermal growthfactor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther. (1999) 82:207–218.
   PubMed Web of Science ®Google Scholar
• CARDIELLO F et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053–2063.
   PubMed Web of Science ®Google Scholar
• KUMAR CC, ARMSTRONG L: Tumor-induced angiogenesis: a novel target for drug therapy? Emerging Drugs: The Prospect Jr Improved Medicines (1998) 3:176–190.
   Google Scholar
• VEIKKOLA T, ALITALO K: VEGF receptors and angiogenesis. Semin. Cancer Biol. (1999) 9:211–220.
   PubMed Web of Science ®Google Scholar
• Investigational Drugs Database. © Current Drugs Ltd., London, UK.
   Google Scholar
• FONG TA, SHAWVER LK, SUN L et al.: 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple types. Cancer Res. (1999)59:99–106.
   PubMed Web of Science ®Google Scholar
• HERMANSON M, FUNA K, HARTMAN M et al.: Platelet derived growth factor receptor in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. (1992) 52:3213–3219.
   PubMed Web of Science ®Google Scholar
• SEBOLT-LEOPOLD JS, DUDLEY DT, HERRERA R et al.: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. (1999) 7:810–816.
   Google Scholar
• ••Important study showing the antitumoreffects of MEK inhibitors.
   Google Scholar
• SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase inhibitors. J. Natl. Cancer Inst. (2000) 92:376–387.
   PubMed Web of Science ®Google Scholar
• GRAVES JD, KREBS EG: Protein phosphorylation and signal transduction. Pharmacol. Ther. (1999) 82:111–121.
   PubMed Web of Science ®Google Scholar